Patents
US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026
25 patents granted to the 4 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to CervoMed Inc.’s names, not what it holds today.
Patents granted
25
25 utility, 1976 to Dec 31, 2025
Granted in 2025
none
in the last year the record reads
Applications published
42
2 of them in 2025
Names they are printed under
4
a former name, a subsidiary
By yearGrantedApplications published
'11'12'13'14'15'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name4 counted
DIFFUSION PHARMACEUTICALS LLC a former name
US, as the owner printed on each patent
18 publishedEIP Pharma, LLC a subsidiary
US, as the owner printed on each patent
10 publishedDIFFUSION PHARMACEUTICALS LLC a former name
named as the applicant on its applications, in US
10 publishedEIP Pharma, LLC a subsidiary
named as the applicant on its applications, in US
4 published
Newest grantseach row opens the USPTO’s own copy
| Granted | Patent | Title | Field | Owner as printed |
|---|
| Nov 8, 2022 | 11,491,129 | Oral formulations of bipolar trans carotenoids | Pharmaceuticals | DIFFUSION PHARMACEUTICALS LLC |
| Oct 11, 2022 | 11,466,008 | Co-crystals of neflamapimod (VX-745) | Pharmaceuticals | EIP Pharma, LLC |
| Mar 22, 2022 | 11,278,621 | Trans carotenoids, their synthesis, formulation and uses | Pharmaceuticals | DIFFUSION PHARMACEUTICALS LLC |
| Nov 30, 2021 | 11,185,523 | Use of bipolar trans carotenoids with chemotherapy and radiotherapy for treatment of cancer | Pharmaceuticals | DIFFUSION PHARMACEUTICALS LLC |
| Oct 19, 2021 | 11,147,859 | Diffusion enhancing compounds and their use alone or with thrombolytics | Pharmaceuticals | DIFFUSION PHARMACEUTICALS LLC |
| May 19, 2020 | 10,653,695 | Pharmaceutical formulations of neflamapimod | Pharmaceuticals | EIP Pharma, LLC |
| Sep 24, 2019 | 10,420,770 | Compositions and methods for treating dementia | Pharmaceuticals | EIP Pharma, LLC |
| Nov 20, 2018 | 10,130,689 | Diffusion enhancing compounds and their use alone or with thrombolytics | Pharmaceuticals | DIFFUSION PHARMACEUTICALS LLC |
| Jul 10, 2018 | 10,016,384 | Oral formulations of bipolar trans carotenoids | Pharmaceuticals | DIFFUSION PHARMACEUTICALS LLC |
| Apr 24, 2018 | 9,950,067 | Trans carotenoids, their synthesis, formulation and uses | Pharmaceuticals | DIFFUSION PHARMACEUTICALS LLC |
Newest applications publishedan application is a clue, never a plan
| Published | Application | Title | Field | Owner as printed |
|---|
| Dec 25, 2025 | 2025/0387399 | TREATMENT OF A SELECTIVE POPULATION OF PATIENTS HAVING DEMENTIA WITH LEWY BODIES | Pharmaceuticals | EIP Pharma, LLC |
| Nov 6, 2025 | 2025/0339435 | TREATMENT OF A SELECTIVE POPULATION OF PATIENTS HAVING DEMENTIA WITH LEWY BODIES | Pharmaceuticals | EIP Pharma, LLC |
| Sep 26, 2024 | 2024/0316000 | METHODS OF TREATMENT | Pharmaceuticals | DIFFUSION PHARMACEUTICALS LLC |
| Sep 12, 2024 | 2024/0300882 | CRYSTALLINE FORMS OF A DIFFUSION ENHANCING COMPOUND | Organic fine chemistry | DIFFUSION PHARMACEUTICALS LLC |
| Dec 21, 2023 | 2023/0405005 | TREATMENT OF GAIT DYSFUNCTION IN NEURODEGENERATIVE DISEASE | Pharmaceuticals | EIP Pharma, LLC |
| Nov 2, 2023 | 2023/0346733 | ORAL FORMULATIONS OF BIPOLAR TRANS CAROTENOIDS | Pharmaceuticals | DIFFUSION PHARMACEUTICALS LLC |
| Jun 15, 2023 | 2023/0181509 | THE USE OF DIFFUSION ENHANCING COMPOUNDS FOR TREATMENT OF VIRAL AND BACTERIAL INDUCED RESPIRATORY DISEASE | Pharmaceuticals | DIFFUSION PHARMACEUTICALS LLC |
| Dec 8, 2022 | 2022/0387589 | TRANS CAROTENOIDS, THEIR SYNTHESIS, FORMULATION AND USES | Pharmaceuticals | DIFFUSION PHARMACEUTICALS LLC |
| Dec 8, 2022 | 2022/0387432 | COMPOSITIONS AND METHODS FOR TREATING PRION DISEASE | Pharmaceuticals | EIP Pharma, LLC |
| Aug 25, 2022 | 2022/0265592 | USE OF BIPOLAR TRANS CAROTENOIDS WITH CHEMOTHERAPY AND RADIOTHERAPY FOR TREATMENT OF CANCER | Pharmaceuticals | DIFFUSION PHARMACEUTICALS LLC |
What it applied for, 2024 to 2025: Pharmaceuticals 3 · Organic fine chemistry 1.
A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.